Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t.co/h3OEJyY3Vr
エルナン先生のついっと。 重症化を検知する、であれば、CT撮りまくる方が効率は良いのかも(欧州のボリュームだと、それも難しいと思うけど)
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t.co/h3OEJyY3Vr
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
Gracias @sefh_ por compartir #SinCienciaNoHayFuturo
En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio) 📚https://t.co/Pj5SFy7O9R 📚https://t.co/hLU3ikWi7m 📚https://t.co/0H6KQIlBan 📚https://t.co/i9xGXvSKgu Resumen @SEMERGENap👉🏻 htt
RT @One_Health_In: "Is early treatment with tocilizumab associated with a lower mortality rate among critically ill patients with coronavir…
Como siempre
RT @drjohnm: Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY W…
RCTs are important, otherwise we will waste a lot of time & energy
Agree. Don’t miss the important bmj piece by @mgtmccartney mentioned in tweet below. We need to study drug and non-drug interventions to inform our response to future pandemics.
RT @drjohnm: Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY W…
Mandrola's right on the spot
RT @drjohnm: Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY W…
RT @drjohnm: Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY W…
RT @drjohnm: Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY W…
RT @dnunan79: Yep. https://t.co/SxIRK4lbbA Most disappointing for me is when these studies include authors who “write the books” on “bet…
RT @drjohnm: Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY W…
Yep. https://t.co/SxIRK4lbbA Most disappointing for me is when these studies include authors who “write the books” on “better research...” etc. A rare thing it is proving to find someone who talks the talk + walks the walk.
RT @drjohnm: Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY W…
Classic case of science overconfidence: Tocilizumab looked great in a large observational study https://t.co/EBiBXr9wsY When tested in proper trials> Nada. Like many things #COVID19 Instead of being so sure, we could promote RCTs not just for med
RT @PharmaVik: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/3FM5ziXSpo via @JAMA…
Eine dritte Studie zeigte eine deutliche Reduktion der Mortalität, die allerdings in der Kontrollgruppe eher ungewöhnlich hoch war. Abwarten, bisher sind die Ergebnisse widersprüchlich. https://t.co/j5rGoC0t3T
RT @RealTimeCOVID19: Just out! 2 RCTs showed NO benefit with #Tocilizumab; 1 non-RCT study showed mortality benefit if given within 2 days…
RT @ATS_BSHSR: Association Between Early Treatment With #Tocilizumab and #Mortality #Among #Critically #Ill Patients With #COVID- #19 #Crit…
RT @DavidLeaf9: Congrats to all the STOP-COVID Investigators on this important work! Early Treatment With Tocilizumab and Mortality Among…
RT @RealTimeCOVID19: Just out! 2 RCTs showed NO benefit with #Tocilizumab; 1 non-RCT study showed mortality benefit if given within 2 days…
Association Between Early Treatment With #Tocilizumab and #Mortality #Among #Critically #Ill Patients With #COVID- #19 #CriticalCare #ICU https://t.co/FynkZ1NJjj https://t.co/URnnR1FsLi
RT @irodriguezpenin: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/QSzkwq0QGg a t…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @PharmaVik: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/XgIU8tWlkD via @JAMA…
RT @worldallergy: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19…
RT @Interasma: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 |…
RT @BrighamResearch: In @JAMAInternalMed: Examining Association Between Early Treatment With Tocilizumab, Risk of Death Among Critically Il…
In @JAMAInternalMed: Examining Association Between Early Treatment With Tocilizumab, Risk of Death Among Critically Ill COVID-19 Patients @DavidLeaf9 https://t.co/kjaSOYefyq (1/4)
うおーJAMA3本目・・・アメリカから、ICU患者4485人の前向きコホート。11%が入室2日以内にtocilizumab投与。より若くて合併症が少なく、重症。ステロイド投与も多かった。 院内死亡率はtocilizumab投与群の方が良かった。 https://t.co/JyvG96hsku
RT @ABsteward: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 STOP-COVID https://t.co/skt45vg…
@jinitsoni3 These on @JAMA_current i do hope it works though, even if for a limited amount of patients with defined criteria
@Inserm Suggestion d'une réduction de la mortalité sur une cohorte multicentrique mais de patients non comparables avec les RCTs car patients hospitalisés en réanimation, & critère de jugement différent i.e. reduction de la mortalité : HR, 0.71; 95%CI,
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/XgIU8tWlkD via @JAMAInternalMed part of @JAMANetwork
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/3FM5ziXSpo via @JAMAInternalMed part of @JAMANetwork
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @worldallergy: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19…
RT @Interasma: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 |…
RT @worldallergy: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19…
RT @worldallergy: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19…
RT @worldallergy: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
@methodsmanmd @NEJM Ahem
RCT>observacional https://t.co/VLgI4f8po2
@VPrasadMDMPH 🤔👇 Two days ago.... https://t.co/4GjWMH6LsY
RCTs comes at you fast...https://t.co/Cr22E9slpo @lucasmorin_eolc @Pottegard https://t.co/HXP3tYDQlU
Covers two trials and an observational report, also free to read: https://t.co/rPSllvMQeZ https://t.co/4GdOrOOGhV https://t.co/7lTPVdsZmc
RT @worldallergy: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19…
Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 | Critical Care Medicine | JAMA Internal Medicine | JAMA Network https://t.co/em6ckhc2Up, see more https://t.co/yY235TM04T
RT @TrubianoJason: #COVID19 #Tocilizumab - 3 new trials. 2 RCT 1 cohort @JAMAInternalMed. No difference in mortality in RCTs. Still absenc…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @hrkz1985: ICUに入室したCOVID-19に対するトシリズマブの効果を、観察研究で検討。院内死亡が減少した。 https://t.co/ZebxX7MVZQ
Lee el artículo completo aquí 👉🏻 https://t.co/zm4CKiK1KH o solicítalo a: [email protected]">@cmcaracas.com.ve">[email protected] #BibliotecaCMC #COVID19
RT @ShrutiGkidney: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/7s4BDPjLkW via @…
RT @hrkz1985: ICUに入室したCOVID-19に対するトシリズマブの効果を、観察研究で検討。院内死亡が減少した。 https://t.co/ZebxX7MVZQ
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @ABsteward: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 STOP-COVID https://t.co/skt45vg…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
ICUに入室したCOVID-19に対するトシリズマブの効果を、観察研究で検討。院内死亡が減少した。 https://t.co/ZebxX7MVZQ
"Is early treatment with tocilizumab associated with a lower mortality rate among critically ill patients with coronavirus disease 2019 (COVID-19)?" Find the answer from @JAMAInternalMed https://t.co/W1SLNdBVi7 https://t.co/SFOOwhigEB
RT @KiraNewmanMDPhD: For those interested— The RCTs: https://t.co/NvQC8k2EFI https://t.co/mNukfAZlQB The cohort study: https://t.co/PQZQ…
RT @irodriguezpenin: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/QSzkwq0QGg a t…
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/QSzkwq0QGg a través de @JAMAInternalMed part of @JAMANetwork
RT @ventilacionmeca: Estudio con Tocilizumab en pacientes críticos. Ojo es un estudio no aleatorizado. Early Treatment With Tocilizumab a…
Association Between Early Treatment With #Tocilizumab and Mortality Among Critically Ill Patients With #COVID19 A total of 1544 patients (39.3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not treated with tocilizumab. https://t
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 STOP-COVID https://t.co/skt45vggz0 via @JAMAInternalMed part of @JAMANetwork https://t.co/fxten8YmoK
"...risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission..." @pash22 @giridar100 @Dharmen46587056 @abledoc @ProfSomashekhar @anupampom @ThinkActTank https://t.co/qbU1Lb1wK6
RT @ventilacionmeca: Estudio con Tocilizumab en pacientes críticos. Ojo es un estudio no aleatorizado. Early Treatment With Tocilizumab a…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
"the risk of in-hospital #COVID19 death was estimated to be lower with #Tocilizumab treatment in the first 2 days of intensive care unit admission compared with no early use of tocilizumab" @JAMAInternalMed
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…